Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Fax: 31 71 524 7445

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

Noobnr1 Jun. 10 at 9:43 AM

$CRSP $GILD $PFE $PHAR $DVAX Now is the time to shine 🤩🚀💎🌪️

0 · Reply

BiotechBonesaw Jun. 9 at 2:03 PM

$KALV - Kalvista is still a buy ahead of their PDUFA $PHVS - Pharvaris is a hold well ahead of their HAE activity in 2026 $PHAR - I would sell or avoid this. Pharming will likely lose market shares or valuation with Kalvista’s expected approval & continued rise

1 · Reply

BiotechBonesaw Jun. 3 at 2:47 PM

$PHAR surprised this is running up ahead of $KALV approval in HAE. GLL biotech investors but I would avoid PHAR $ $PHVS until Kalvista does their thing

1 · Reply

Dutchindo Jun. 3 at 8:18 AM

$PHAR 52 wk high 📈

0 · Reply

PenkeTrading May. 9 at 4:10 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Pharming Group NV. Is that bullish or bearish? $PHAR #Pharming #RsiOverbought #NASDAQ

0 · Reply

SannieVerraderlijk May. 8 at 8:54 AM

$PHAR https://www.globenewswire.com/news-release/2025/05/08/3076806/0/en/Pharming-Group-reports-first-quarter-2025-financial-results-and-provides-business-update.html

0 · Reply

SannieVerraderlijk May. 8 at 8:54 AM

$PHAR Great earnings, buy now premarket if you can. Up 17% in Europe

1 · Reply

Declan1NL May. 8 at 8:05 AM

$PHAR It will explot to day 42% more profit

1 · Reply

Armonica423 May. 7 at 1:53 AM

$PHAR CYDY

0 · Reply

Bamster Apr. 28 at 4:35 PM

Long term for me: $OMEX extract minerals from the sea. We are getting a shorter everyday. With approval of the 🍊 guy $QBTS quantum, do I need to say more?💾 $ASML without this company no minuscule chips🍪 and the best machines for this $PHAR got some nice drugs trails drug💊 $MBRX possibility for cancer treatment. 👨‍🦲

0 · Reply

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

May 28, 2025, 2:00 AM EDT - 19 days ago

Pharming Group to participate in June investor conferences

May 9, 2025, 8:50 AM EDT - 5 weeks ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 5 weeks ago

Pharming Group reports first quarter 2025 financial results and provides business update

Apr 30, 2025, 11:45 AM EDT - 6 weeks ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 24, 2025, 2:00 AM EDT - 7 weeks ago

Pharming Group to report first quarter 2025 financial results on May 8

Apr 23, 2025, 3:30 AM EDT - 7 weeks ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 3, 2025, 1:00 AM EDT - 2 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Mar 28, 2025, 3:00 AM EDT - 2 months ago

Pharming Group to participate in April investor conferences

Mar 13, 2025, 7:44 PM EDT - 3 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 3 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 4, 2025, 9:15 AM EST - 3 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Feb 7, 2025, 4:00 PM EST - 4 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Jan 21, 2025, 12:00 PM EST - 5 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 1:00 AM EST - 5 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Dec 15, 2024, 1:45 PM EST - 6 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 11, 2024, 9:34 AM EST - 6 months ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Nov 5, 2024, 2:00 AM EST - 7 months ago

Pharming Group to participate in November investor conference

Oct 24, 2024, 1:44 PM EDT - 8 months ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 10, 2024, 2:00 AM EDT - 8 months ago

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 1:00 AM EDT - 8 months ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Sep 26, 2024, 1:00 AM EDT - 9 months ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 4, 2024, 1:00 AM EDT - 10 months ago

Pharming Group to participate in September investor conferences

Aug 2, 2024, 3:26 PM EDT - 11 months ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 1:00 AM EDT - 11 months ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Jul 18, 2024, 2:00 AM EDT - 11 months ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 8, 2024, 1:00 AM EDT - 1 year ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 4, 2024, 2:30 AM EDT - 1 year ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Apr 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Mar 14, 2024, 1:15 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 2:00 AM EDT - 1 year ago

Pharming Group reports fourth quarter and full year 2023 financial results

Feb 29, 2024, 2:00 AM EST - 1 year ago

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Feb 8, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in February investor conferences

Jan 8, 2024, 1:00 AM EST - 1 year ago

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Dec 13, 2023, 1:00 AM EST - 1 year ago

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Nov 10, 2023, 8:51 AM EST - 1 year ago

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Nov 7, 2023, 2:00 AM EST - 1 year ago

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Nov 1, 2023, 3:00 AM EDT - 1 year ago

Pharming Group to participate in November investor conferences

Oct 27, 2023, 8:35 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript

Oct 26, 2023, 10:33 PM EDT - 1 year ago

Pharming Group N.V. (PHGUF) Q3 2023 Earnings Call Transcript

Noobnr1 Jun. 10 at 9:43 AM

$CRSP $GILD $PFE $PHAR $DVAX Now is the time to shine 🤩🚀💎🌪️

0 · Reply

BiotechBonesaw Jun. 9 at 2:03 PM

1 · Reply

BiotechBonesaw Jun. 3 at 2:47 PM

$PHAR surprised this is running up ahead of $KALV approval in HAE. GLL biotech investors but I would avoid PHAR $ $PHVS until Kalvista does their thing

1 · Reply

Dutchindo Jun. 3 at 8:18 AM

$PHAR 52 wk high 📈

0 · Reply

PenkeTrading May. 9 at 4:10 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Pharming Group NV. Is that bullish or bearish? $PHAR #Pharming #RsiOverbought #NASDAQ

0 · Reply

SannieVerraderlijk May. 8 at 8:54 AM

$PHAR https://www.globenewswire.com/news-release/2025/05/08/3076806/0/en/Pharming-Group-reports-first-quarter-2025-financial-results-and-provides-business-update.html

0 · Reply

SannieVerraderlijk May. 8 at 8:54 AM

$PHAR Great earnings, buy now premarket if you can. Up 17% in Europe

1 · Reply

Declan1NL May. 8 at 8:05 AM

$PHAR It will explot to day 42% more profit

1 · Reply

Armonica423 May. 7 at 1:53 AM

$PHAR CYDY

0 · Reply

Bamster Apr. 28 at 4:35 PM

0 · Reply

Thestocktraderhubzee Apr. 23 at 9:56 AM

WATCHLIST APR 23 2025 $TOI The Oncology Institute Announces Enterprise-wide Expansion Of Strategic Partnership With Helios Clinical Research $SNOA Sonoma Pharmaceuticals shares are trading higher after the company announced the registration and launch of new products in the UK. $CSCO Rosenblatt Maintains Buy on Cisco Systems, Lowers Price Target to $63 $PHAR Pharming Group Announces That The National Institute For Health And Care Excellence (Nice) Has Issued Positive Final Guidance Recommending Joenja (Leniolisib) Within The National Health Service In England And Wales For The Treatment Of Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) $FICO FICO And Dacadoo Have Partnered To Enhance The Way Insurance Companies Can Assess And Manage Risk, Promote Health/Wellness, And Improve Customer Engagement

0 · Reply

SannieVerraderlijk Apr. 23 at 8:00 AM

$PHAR Up she goes https://www.globenewswire.com/news-release/2025/04/23/3066101/0/en/Pharming-receives-positive-recommendation-from-NICE-for-Joenja-leniolisib-as-a-treatment-for-APDS.html

0 · Reply

LewisDaKat Apr. 4 at 7:25 PM

$PHAR News Article Objective long/short (PHAR) Report https://marketwirenews.com/news-releases/objective-long-short-phar-report-7428609299406215.html $PHAR

0 · Reply

Noobnr1 Mar. 21 at 6:46 PM

$PHAR 🚀🚀🚀🚀 $DVAX $PFE $GILD 🙏🚀🚀🙏 🥳🍾🥳🍾

0 · Reply

JarvisFlow Mar. 21 at 12:00 PM

HC Wainwright & Co. updates rating for Pharming ( $PHAR ) to Buy, target set at 37.

0 · Reply

JarvisFlow Mar. 20 at 3:16 PM

HC Wainwright & Co. has adjusted their stance on Pharming ( $PHAR ), setting the rating to Buy with a target price of 37.

0 · Reply

Thestocktraderhubzee Mar. 20 at 8:35 AM

WATCHLIST MAR 20 2025 $CPIX Cumberland Pharmaceuticals Announced Results From Its Phase 2 FIGHT DMD Clinical Trial Were Selected For Late-breaking Presentation At The Muscular Dystrophy Association Clinical & Scientific Conference In Dallas $SPNT SiriusPoint Announces Strategic Partnership With Holmes Murphy To Launch New Captive-Focused Umbrella Excess Insurance Product $BKKT Bakkt Enters Strategic Partnership With Distributed Technologies Research To Integrate Stablecoin-Based Payments Technology Infrastructure $TXO TXO Partners Says Bob Simpson Will Retire From The Office Of CEO Of General Partner, Effective April 1, 2025; Gary Simpson And Brent Clum Both To Be Promoted To Serve As Co-CEOs $PHAR Pharming Doses First Patient In Phase II Trial of Leniolisib For CVID With Immune Dysregulation

0 · Reply

JarvisFlow Mar. 14 at 4:38 PM

Oppenheimer has adjusted their stance on Pharming ( $PHAR ), setting the rating to Outperform with a target price of 30 → 39.

0 · Reply

garygb Mar. 14 at 4:37 PM

$PHAR Sign me up

0 · Reply

JarvisFlow Mar. 14 at 11:00 AM

HC Wainwright & Co. updates rating for Pharming ( $PHAR ) to Buy, target set at 37.

0 · Reply

Ruconestor Mar. 13 at 2:41 PM

$PHAR still undervalued Go go go. ⬆️⬆️⬆️

0 · Reply

OpenOutcrier Mar. 13 at 12:37 PM

$PHAR (+10.7% pre) Pharming Group reports fourth quarter and full year 2024 financial results and provides business update https://ooc.bz/l/59379

0 · Reply

Market Cap	731.33M
Revenue (ttm)	297.20M
Net Income (ttm)	-11.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.98%
Debt to Equity Ratio	0.02

Volume	5,054
Avg Vol	4,066
Day's Range	N/A - N/A
Shares Out	68.03M
Stochastic %K	16%
Beta	0.02
Analysts	Strong Sell
Price Target	$30.33